Ken Mariash Email & Phone Number

Cambridge, MA, US

Invented by Profs Giacomo Koch MD, PhD and Emiliano Santarnecchi, PhD, PsyD, Sinaptica is developing closed-loop neuromodulation therapy for Alzheimer's with published Phase 2 sham-controlled efficacy which is highly statistically significant on four gold-standard cognitive and functional endpoints, and is more pronounced than any drug to date, earning FDA.

A "decision" can be defined as an irrevocable commitment of resources. We help leadership make the big investment decisions: around fundraising, portfolio, market entry, M&A, and launch strategy. We support decision-making with quantitative pricing studies, market validation research, CAC assessment, decision analysis, and go-to-market strategy (including.

Toronto, Ontario, CA

• Full-time employee #2 overseeing all commercial aspects
• Product - Owned user requirements for novel neurostimulator + companion app, from napkin sketch to V&V in 2.5 yrs. Oversaw ethnographic and human factors-driven design &development incl UI/UX.
• GTM - Developed go-to-market strategy including salesforce planning, positioning/messaging, telemedicine, pricing, reimbursement, direct-to-patient promo, and organizational expansion plan.
• Market Research - Drove six market validation studies including online CAC and pricing exercises.
• Physician Marketing - Authored physician influence plan and successfully engaged 40+ KOLs.
• R&D Roadmap - Commercial input to clinical strategy and long-term product / indication roadmaps.

Marlborough, MA, US

• WW Franchise Lead - Drove 2016 acquisition of the Cosman RF ablation business, providing leadership impacting nearly every aspect of integration and ongoing operations, including product roadmap, sales force model and.
• Results: Cosman growth strongly outperformed deal model, trending a full year ahead of plan and continues to outperform 5 years later.
• Head of Strategy - Founded and led divisional Strategy function for 8 years as sales nearly tripled from ~$300M to ~$900M, with responsibility for strategic planning, market research, CI, business analytics, R&D.
• Digital Strategy - Co-authored division's digital strategy including connectivity, companion apps, and remote patient mgmt, which won an $8-digit incremental funding commitment.
• Implantable Development & Launch - Participated in the needs-assessment, design, development, launch, and scaling of several implantable stimulators including Precision Spectra™️ (Prix Galien nominee) and WaveWriter™️..
• Companion Apps - Drove JV with BCG Digital Ventures which resulted in PainScale, the first digital 'product' for BSN.

Deerfield, Illinois, US

• Led strategic market assessments
• Evaluated and championed acquisitions
• Drove business planning for multiple franchises
• Facilitated corporate strategy development
• Supported Sr leadership in crafting & articulating long-term vision
• Key driver of R&D portfolio management process

Melbourne, Victoria, AU

• Key contributor to US launch of Carimune, a $300M biologic immunotherapy
• Created marketing plans, branding guidelines
• Supported advisory boards on positioning/messaging, and on clinical trial design
• Executed pre-launch activities for Carimune's successor formulation
• Pointperson for KPIs, pricing, and supply chain analytics

Boston, MA, US

• Contributed to strategic recommendations for blockbuster Big Pharma launches
• Conceived and drove development of DirectEvent®, a proprietary financial analysis software tool
• Contributor on numerous asset valuation engagements
• Healtheconomic research on the value of various drugs and medical devices

Boston, MA, US

Supported three professors of finance in their original research on investment decisions and risk arbitrage.